Status:
UNKNOWN
Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19
Lead Sponsor:
Great Ormond Street Hospital for Children NHS Foundation Trust
Conditions:
COVID19
Eligibility:
All Genders
3+ years
Brief Summary
COVID19 pandemic currently represents a public health emergency. Based on current data, 15% of the affected individuals will develop a severe form of the disease requiring admission to hospital and re...
Detailed Description
The transplant teams in each participating site will be identifying and approaching eligible patients. Adult and paediatric patients with a history of allogeneic stem cell transplantation who are admi...
Eligibility Criteria
Inclusion
- Adult and paediatric patents (any age) who have received allogeneic stem cell transplantation AND
- Proven COVID19 infection as documented by PCR testing of nasal/ throat swab or NPA AND
- Severe COVID 19 infection as defined by need for supplemental oxygen
Exclusion
- Patients beyond the first 72 hours of developing oxygen requirement or
- Patients who have received cytokine targeting treatment before blood sampling or
- Patients with a mild/moderate COVID19 infection (ie no need for supplementary oxygen)
Key Trial Info
Start Date :
April 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 15 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04349540
Start Date
April 15 2020
End Date
January 15 2021
Last Update
April 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Great Ormond Street Hospital NHS Foundation Trust
London, United Kingdom, WC1N 3 JH